JYSELECA Emerging Drug Insight

“JYSELECA Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about JYSELECA (Filgotinib) for Crohn’s disease (CD) in the 7MM. A detailed picture of the JYSELECA (Filgotinib) for Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the JYSELECA (Filgotinib) for Crohn’s disease (CD). The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JYSELECA (Filgotinib) market forecast, analysis for Crohn’s disease (CD) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Crohn’s disease (CD).

Drug Summary

Filgotinib is an orally bioavailable, investigational agent with potential anti-inflammatory and immunomodulating activities, discovered and developed by Galapagos in collaboration with Gilead. It is a selective JAK1 (Janus kinase 1) inhibitor. JAK1 is an enzyme with an essential role in the promotion of biologic responses induced by a subset of cytokine receptors, proteins that lead to inflammation. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling.

As JAK1 mediates the signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies. Filgotinib (200 mg and 100 mg tablets) is approved and marketed as Jyseleca in Europe and Japan for the treatment of adults with moderately to severely active RA (DMARDs).

Currently, Filgotinib is in the Phase III clinical development stage in the US for both the indications of Crohn's disease and Ulcerative Colitis. In Ulcerative Colitis, Gilead completed a Phase III trial with filgotinib (NCT02914522, SELECTION1) and is currently conducting another Phase III study (NCT02914535, SELECTIONLTE). Whereas, in Crohn's disease, two Phase III clinical trials are still ongoing (NCT02914561, DIVERSITY1) and (NCT02914600, DIVERSITYLTE). Other than these studies, filgotinib is also being investigated in two Phase II trials.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the JYSELECA (Filgotinib) description, mechanism of action, dosage and administration, research and development activities in Crohn’s disease (CD).
•  Elaborated details on JYSELECA (Filgotinib) regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the JYSELECA (Filgotinib) research and development activity in Crohn’s disease (CD) in detail across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around JYSELECA (Filgotinib).
•  The report contains forecasted sales of JYSELECA (Filgotinib) for Crohn’s disease (CD) till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Crohn’s disease (CD).
•  The report also features the SWOT analysis with analyst views for JYSELECA (Filgotinib) in Crohn’s disease (CD).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

JYSELECA (Filgotinib) Analytical Perspective by DelveInsight

• In-depth JYSELECA (Filgotinib) Market Assessment

This report provides a detailed market assessment of JYSELECA (Filgotinib) in Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• JYSELECA (Filgotinib) Clinical Assessment

The report provides the clinical trials information of JYSELECA (Filgotinib) in Crohn’s disease (CD) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Crohn’s disease (CD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence JYSELECA (Filgotinib) dominance.
•  Other emerging products for Crohn’s disease (CD) are expected to give tough market competition to JYSELECA (Filgotinib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JYSELECA (Filgotinib) in Crohn’s disease (CD).
•  Our in-depth analysis of the forecasted sales data of JYSELECA (Filgotinib) from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the JYSELECA (Filgotinib) in Crohn’s disease (CD).

Key Questions

•  What is the product type, route of administration and mechanism of action of JYSELECA (Filgotinib)?
•  What is the clinical trial status of the study related to JYSELECA (Filgotinib) in Crohn’s disease (CD) and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JYSELECA (Filgotinib) development?
•  What are the key designations that have been granted to JYSELECA (Filgotinib) for Crohn’s disease (CD)?
•  What is the forecasted market scenario of JYSELECA (Filgotinib) for Crohn’s disease (CD)?
•  What are the forecasted sales of JYSELECA (Filgotinib) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Crohn’s disease (CD) and how are they giving competition to JYSELECA (Filgotinib) for Crohn’s disease (CD)?
•  Which are the late-stage emerging therapies under development for the treatment of Crohn’s disease (CD)?